Driver genomic fusions [e.g. anaplastic lymphoma kinase (ALK), ROS1, and KIF5B-RET fusion, etc.] are thought not to be correlated with smoking-associated mutations and frequently served as driver events of smoking-signature-low lung adenocarcinomas. This evidence concerns the gene ALK and lung adenocarcinoma.